Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Study Also Show Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, VIENNA, Austria, ... being developed by Organon -- is effective,in treating acute manic episodes ... studies, were presented this week at,the 20th European College of Neuropsychopharmacology ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... granted approval of IXEMPRA(TM) (ixabepilone) as,monotherapy for the ... cancer in patients whose tumors are resistant or ... also granted,approval of IXEMPRA in combination with capecitabine ...
... Senior Management Team, ROCKVILLE, Md., Oct. 16 ... pharmaceutical company developing,therapeutics for the treatment of cancer ... Ph.D. has been appointed its Senior Vice,President, Research ... an,executive officer of EntreMed by the Board of ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:4/17/2014)... German . ... demanded of him, he can expect his premises to be ... of the consequences is enough to make restaurant owners pay ... lay their eggs in other birds, nests. If the host ... their revenge by destroying the entire nest. Consequently, it is ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... was until now believed that nocturnally migrating songbirds, while ... long, challenging trans-continental migrations, could at least release anti-predator ... study by Spanish and Swiss scientists ?published this week ... not without predation risk for passerines. , A ...
... be reunited with its owner than a lost cat, according to two ... that 71 percent of lost dogs were found, compared to just 53 ... recovered dogs were found by a call or visit to an animal ... wore a dog license or identification tag at the time of its ...
... mean big things for cancer patients in the future. Gary ... of Kentucky published their findings today in Nature Genetics, an ... stem cell gene and its protein product, Laxetin, and building ... to the identification of the gene itself. This is the ...
Cached Biology News:Bats prey on nocturnally migrating songbirds 2Bats prey on nocturnally migrating songbirds 3Bats prey on nocturnally migrating songbirds 4Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Researchers first to map gene that regulates adult stem cell growth 2
This depletion cocktail is tailored to deplete IgE-bearing (I.e. basophils and mast cells) from whole blood...
... gels The SpinPrep Gel DNA Kit enables efficient ... 12,000 bp in size from agarose gels. The procedure ... by adsorption of the DNA to a silica membrane ... the purified DNA is eluted in low-salt buffer. Each ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
Biology Products: